Genome-wide association studies have implicated the *TERT-CLPTM1L* locus at 5p15.33 in susceptibility to a variety of cancers including pancreas, lung, skin and glioma, suggesting that *TERT* may act as a "pan-cancer susceptibility locus" in a similar manner to the 8q24 region.

We initially identified an association between an intronic *TERT* SNP rs7726159 and epithelial ovarian cancer (EOC) risk through an Illumina GoldenGate scan of single nucleotide polymorphisms (SNPs) in candidate genes, with a more pronounced effect in serous cases (Johnatty et al, PloS Genetics 2010). We employed a fine-mapping strategy of a 500 kb region of the *TERT-CLPTM1L* locus using data from the 1000Genomes and HapMap Projects, and cases and controls from the Ovarian Cancer Association Consortium (OCAC). Using single-marker and stepwise logistic regression adjusted for age and study, we analysed 28 SNPs in 2,130 invasive epithelial ovarian cancer cases, including 1,076 of serous histology, and 3,975 controls of Caucasian ancestry from nine OCAC studies, and observed a significant association between serous cases and a *TERT* promoter SNP rs2736109 \[adj. OR~per-allele~ 0.86 (0.77-0.96), *P* = 0.005\].

Since much of the genetic architecture is shared between EOC and breast cancer, we analysed rs2736109 in 4,277 invasive breast cancer cases and 7,000 controls from the Breast Cancer Association Consortium (BCAC). Although there was no association with invasive breast cancer risk overall \[adj. OR~per-allele~ = 0.95 (0.90 - 1.01) *P* = 0.10\], we found the strongest evidence of association among ER-negative cases over the age of 50 (n=636) \[adj. OR~per-allele~ 0.84 (0.75-0.95), *P* = 0.005\].

To examine the potential functional consequences of rs2736109 and another promoter SNP, rs2736108, we generated luciferase reporter constructs comprising 3.7 kb of the TERT promoter containing various combinations of alleles and transfected them into breast and ovarian cell lines. We observed a decrease in luciferase expression by the presence of both the A alleles at rs2736108 and rs2736109, but not when either allele is present alone. Our analysis of 345 Australian controls suggests that the A-A haplotype at rs2736108 and rs2736109 occurs with a frequency of 32%, suggesting that this relatively common promoter haplotype may lower the risk of serous epithelial ovarian cancer though decreasing TERT expression.
